Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: Evaluation by quantitative contrast-enhanced ultrasonography

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Zhu, Xiao Dong ^a   Zhang, Ju Bo ^a   Fan, Pei Li ^a   Xiong, Yu Quan ^a   Zhuang, Peng Yuan ^a   Zhang, Wei ^a   Xu, Hua Xiang ^a   Gao, Dong Mei ^a   Kong, Ling Qun ^a   Wang, Lu ^a   Wu, Wei Zhong ^a   Tang, Zhao You ^a   Ding, Hong ^a   Sun, Hui Chuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; PAZOPANIB; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BLOOD VESSEL; CELL CULTURE; CELL LINE; CELL STRAIN HEPG2; CELL SURVIVAL; DRUG SCREENING; IMAGE ENHANCEMENT; LIVER TUMOR; METHODOLOGY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOOD VESSELS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRIMIDINES; SULFONAMIDES; TUMOR BURDEN; ULTRASONOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651540931     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-28     Document Type: Article

References (42)

1. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004, 130(6):307-319. 10.1007/s00432-003-0530-y, 15034787.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236. 10.1002/hep.20933, 16250051.
4. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006, 23(11):1535-1547. 10.1111/j.1365-2036.2006.02932.x, 16696801.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
6. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. Journal of Hepatology 2004, 41(5):864-880. 10.1016/j.jhep.2004.09.006, 15519663.
7. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007, 72(Suppl 1):30-44. 10.1159/000111705, 18087180.
8. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005, 65(9):3691-3699. 10.1158/0008-5472.CAN-04-3462, 15867364.
9. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26(18):2992-2998. 10.1200/JCO.2007.15.9947, 18565886.
10. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008, 26(16):2707-2716. 10.1200/JCO.2007.15.6521, 18509183.
11. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008, 112(2):250-259. 10.1002/cncr.23175, 18041064.
12. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8(8):579-591. 10.1038/nrc2403, 18596824.
13. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer 2002, 2(10):727-739. 10.1038/nrc905, 12360276.
14. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008, 13(2):120-125. 10.1634/theoncologist.2007-0174, 18305056.
15. Wang JH, Min PQ, Wang PJ, Cheng WX, Zhang XH, Wang Y, Zhao XH, Mao XQ. Dynamic CT Evaluation of Tumor Vascularity in Renal Cell Carcinoma. AJR Am J Roentgenol 2006, 186(5):1423-1430. 10.2214/AJR.04.1408, 16632740.
16. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?. Eur Radiol 2004, 14(2):309-317. 10.1007/s00330-003-2025-2, 14531000.
17. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006, 24(20):3293-3298. 10.1200/JCO.2006.06.8080, 16829653.
18. Bertolotto M, Pozzato G, Croce LS, Nascimben F, Gasparini C, Cova MA, Tiribelli C. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. Invest Radiol 2006, 41(1):15-21. 10.1097/01.rli.0000188363.93670.45, 16355035.
19. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006, 240(1):73-81. 10.1148/radiol.2401050709, 16793972.
20. Lucidarme O, Kono Y, Corbeil J, Choi SH, Golmard JL, Varner J, Mattrey RF. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 2006, 239(3):730-739. 10.1148/radiol.2392040986, 16714458.
21. Bolondi L, Correas JM, Lencioni R, Weskott HP, Piscaglia F. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig Liver Dis 2007, 39(2):187-195. 10.1016/j.dld.2006.08.008, 17208526.
22. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47(1):97-104. 10.1002/hep.21966, 18069697.
23. Dai Y, Chen MH, Fan ZH, Yan K, Yin SS, Zhang XP. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Res 2008, 38(3):281-290. 10.1111/j.1872-034X.2007.00269.x, 17908168.
24. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008, 48(5):848-857. 10.1016/j.jhep.2008.02.005, 18328590.
25. Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P, Passariello R. Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 1998, 209(2):387-393.
26. Catalano O, Esposito M, Lobianco R, Cusati B, Altei F, Siani A. Hepatocellular carcinoma treated with chemoembolization: assessment with contrast-enhanced doppler ultrasonography. Cardiovasc Intervent Radiol 1999, 22(6):486-492. 10.1007/s002709900437, 10556408.
27. Cioni D, Lencioni R, Rossi S, Garbagnati F, Donati F, Crocetti L, Bartolozzi C. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power doppler sonography to assess treatment outcome. AJR Am J Roentgenol 2001, 177(4):783-788.
28. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7):2012-2021. 10.1158/1535-7163.MCT-07-0193, 17620431.
29. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004, 130(8):460-468. 10.1007/s00432-004-0564-9, 15146329.
30. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15(15):4838-4846. 10.1158/1078-0432.CCR-08-2780, 19638466.
31. Cosgrove D, Eckersley R, Blomley M, Harvey C. Quantification of blood flow. Eur Radiol 2001, 11(8):1338-1344. 10.1007/s003300100985, 11519540.
32. Postert T, Hoppe P, Federlein J, Helbeck S, Ermert H, Przuntek H, Buttner T, Wilkening W. Contrast agent specific imaging modes for the ultrasonic assessment of parenchymal cerebral echo contrast enhancement. J Cereb Blood Flow Metab 2000, 20(12):1709-1716. 10.1097/00004647-200012000-00010, 11129787.
33. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, Raleigh JA. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998, 71(2):270-277. 10.1006/gyno.1998.5163, 9826471.
34. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999, 151(5):580-589. 10.2307/3580034, 10319731.
35. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006, 103(51):19478-19483. 10.1073/pnas.0609329103, 1748251, 17164332.
36. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25(13):1753-1759. 10.1200/JCO.2006.07.3049, 17470865.
37. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9):987-989. 10.1038/nm0901-987, 11533692.
38. Krix M, Kiessling F, Vosseler S, Farhan N, Mueller MM, Bohlen P, Fusenig NE, Delorme S. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 2003, 63(23):8264-8270.
39. Magnon C, Galaup A, Rouffiac V, Opolon P, Connault E, Rose M, Perricaudet M, Roche A, Germain S, Griscelli F, Lassau N. Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration. Gene Ther 2007, 14(2):108-117. 10.1038/sj.gt.3302901, 16943854.
40. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA, Hallscheidt P, Kauffmann GW, Semmler W, Kiessling F. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 2008, 68(17):7042-7049. 10.1158/0008-5472.CAN-08-0285, 18757418.
41. Krix M, Kiessling F, Farhan N, Schmidt K, Hoffend J, Delorme S. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 2003, 29(10):1421-1430. 10.1016/S0301-5629(03)01033-0, 14597339.
42. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol 2008, 5(7):378-391. 10.1038/ncponc1150, 18560389.